Navigation Links
Shire Launches Report that Quantifies the Health, Psycho-social and Economic Impact of Rare Diseases
Date:4/9/2013

K agreed) and more office visits are required to diagnose a rare disease patient (98% in the US, 96% in the UK agreed)
  • In addition, more than half of physicians stated there aren't enough opportunities to network with other physicians who treat rare diseases (54% in the US, 62% in the UK agreed) 
  • From a patient and caregiver perspective, around half of those surveyed stated they received conflicting information from different health care professionals about treatment options (60% in the US, 50% in the UK agreed)
    • In fact, more than half of patients and caregivers stated they needed to provide their healthcare professionals with information on their rare disease (67% in the US, 62% in the UK agreed)
  • As a result of these challenges, on average, it takes 7.6 years in the US and 5.6 years in the UK for a patient with a rare disease to receive a proper diagnosis, based on survey results. Along the way, the average patient visits four primary care doctors, four specialists and receives two to three misdiagnoses
  • The economic impact of diagnosing and managing rare diseases is significant. The journey to diagnosis and beyond comes with a steep price tag for many coping with a rare disease. The long road, which frequently includes numerous tests and physician visits, can become financially overwhelming, particularly for those in the US as compared to the UK 

    • Payor respondents reported several factors contribute to the higher costs of care for rare disease patients compared to more common diseases, including the need for more diagnostic tests (100% in the US, 80% in the UK agreed) and more costly diagnostic tests (100% in the US, 90% in the UK agreed)
    • Payors also found it difficult to make rare disease coverage decisions due to the lack of standards and guidelines. Almost all payors surveye
      '/>"/>

    SOURCE Shire plc
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Shire to Acquire SARcode Bioscience, Expands Presence in Ophthalmology
    2. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
    3. Shire Reaches Agreement in Principle With U.S. Government
    4. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
    5. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
    6. Shire Changes its NASDAQ Ticker Symbol to SHPG
    7. Berkshire Corporation Offers Live Chat For Americas Website and Shopping Cart
    8. Shire Facebook Page Increases Awareness of Hereditary Angioedema (HAE) in Support of First HAE Awareness Day May 16th
    9. Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012
    10. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
    11. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/2/2015)... September 2, 2015 BioLight ... or the "Company"), a firm that invests in, ... cancer diagnostics, announced today that presentations highlighting its ... be delivered at the Ophthalmology Futures European Forum ... of Cataract & Refractive Surgeons ("ESCRS"), both taking ...
    (Date:9/2/2015)... Biovista Inc. freut sich, ... 2015 bekanntgeben zu können. Hierbei handelt es sich ... Biovista unterstützt mit seiner Möglichkeit der Analyse ... Krankheiten als denen, für die ein Medikament ursprünglich ... Team bei der Wylder Nation Foundation bei der ...
    (Date:9/2/2015)... ... 2015 , ... Whitehouse Laboratories is excited to announce that ... upcoming educational seminar and training session on Extractable & Leachable testing. Featuring a ... Updates & Case Studies on the Latest Compliance Implications of USP and ICH ...
    (Date:9/2/2015)... ... September 02, 2015 , ... The ... creating professional commercial video content, to analysis of athletic performance. Producing high-resolution ... go by too quickly to process with the naked eye. , Slow ...
    Breaking Biology Technology:Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 3Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3
    ... , , RESEARCH TRIANGLE PARK, ... today announced that it has completed its acquisition of Stiefel Laboratories, Inc. ... cash consideration of $2.9 billion. GSK also assumed $0.4 billion of ... obligated to make additional cash payments of up to $0.3 billion depending ...
    ... , DUBAI, United Arab Emirates and SAN ... and medical device company serving the Middle East, Africa, Turkey ... an exclusive license and supply agreement with Axcan Pharma for ... eradication of Helicobacter pylori , a bacterium now recognized ...
    ... , , CHICAGO, July ... Chemistry (AACC) annual meeting today indicates that monitoring cardiac transplant ... analyzer may help clinicians to monitor cyclosporine-induced toxicity and adjust ... , , In ...
    Cached Biology Technology:GlaxoSmithKline Completes Acquisition of Stiefel 2NewBridge Pharmaceuticals Announces Licensing of Pylera(R) for Middle East, Africa, Turkey & Caspian Region 2NewBridge Pharmaceuticals Announces Licensing of Pylera(R) for Middle East, Africa, Turkey & Caspian Region 3Investigational Urine NGAL Biomarker Shows Promise to Monitor Cyclosporine Toxicity in Cardiac Transplant Patients 2
    (Date:8/20/2015)... Aug. 20, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market and ... joined The Smart Card Alliance and the EMV Migration ... and the Smart Card Alliance Latin America (SCALA) Chapter ... peers and thought leaders promoting adoption of smart card ...
    (Date:8/12/2015)... Minn. , Aug. 12, 2015   MedNet ... supports the entire spectrum of clinical research, is proud ... , the company,s comprehensive SaaS-based eClinical technology platform, has ... during the first two quarters of 2015.   Q2 ... second largest quarters measured by contract value sold in ...
    (Date:8/10/2015)... Germany , August 10, 2015 /PRNewswire/ ... world leader in Eye Tracking Technology for more than ... Eye Tracking Platform for integration into all consumer display ... designs for seamless integration of eye tracking into consumer ... and augmented reality smart glasses. Omnivision,s leading sensor technology ...
    Breaking Biology News(10 mins):NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4MedNet Solutions Experiences Explosive Corporate Growth 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3
    ... scans to measure blood flow in the lungs of people ... are most at risk of emphysema before the disease damages ... University of Iowa study. The study found that smokers ... normal lung function, have very different blood flow patterns in ...
    ... Chronix Biomedical today announced publication of a study ... tests to predict clinical status and monitor disease activity ... Chronix Biomedical uses proprietary technology to identify disease-specific genetic ... into the bloodstream by damaged and dying cells. ...
    ... 2010) -- A scientist at Barrow Neurological Institute in Phoenix ... Association (MDA) to continue his groundbreaking work in the disease ... part of MDA,s ongoing commitment to fund neuromuscular research that ... and related diseases. Including this funding, the MDA has ...
    Cached Biology News:New test could identify smokers at risk of emphysema 2Chronix Biomedical's serum DNA assays monitor disease activity and treatment response in MS 2Chronix Biomedical's serum DNA assays monitor disease activity and treatment response in MS 3Barrow scientist receives $450K MDA grant 2
    Eagle's Ham's amino acids; EHAA...
    ... provides quick and easy operation of a ... control. The software is fully secure ... CFR Part 11 regulations, and compatible with ... IRsolutions versatility enables use in high-level research ...
    ... random mutations to the gene supplied by a ... a vector of choice to obtain a library ... be set to a desired value within 1-20 ... Mutations can be restricted to a desired ...
    ... Tecans new Enzyme-Linked Immunosorbent Assay (ELISA) analyzer ... is a dedicated EVO platform for reliableELISA ... and incubation units operated by the new ... available in three sizes - 100, 150, ...
    Biology Products: